Guj. Terce Labs.

how big is Guj. Terce Labs.?

As of Jun 06, Gujarat Terce Laboratories Ltd has a market capitalization of 42.00 Cr, classifying it as a Micro Cap company, with recent net sales of 32.25 Cr and a net profit of 1.59 Cr over the last four quarters.

Market Cap: As of Jun 06, Gujarat Terce Laboratories Ltd has a market capitalization of 42.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 32.25 Cr, and the sum of Net Profit for the same period is 1.59 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending Mar'24. Shareholder's Funds are reported at 7.11 Cr, and Total Assets amount to 22.05 Cr.

Who are in the management team of Guj. Terce Labs.?

As of March 2022, the management team of Guj. Terce Labs includes Amrutbhai P Prajapati (Whole-time Director), Aalap Prajapati (Managing Director & CEO), and Natwarbhai P Prajapati (Chairman & Whole-time Director), along with several Independent Directors: Chhayaben Ashwinbhai Shah, Viplav Suryakantbhai Khamar, Surendra Kumar Sharma, and Navinchandra Patel.

As of March 2022, the management team of Guj. Terce Labs includes the following individuals:<BR><BR>1. Amrutbhai P Prajapati - Whole-time Director<BR>2. Chhayaben Ashwinbhai Shah - Independent Director<BR>3. Viplav Suryakantbhai Khamar - Independent Director<BR>4. Aalap Prajapati - Managing Director & CEO<BR>5. Surendra Kumar Sharma - Independent Director<BR>6. Navinchandra Patel - Independent Director<BR>7. Natwarbhai P Prajapati - Chairman & Whole-time Director<BR><BR>These members play various roles within the company's governance and management structure.

When is the next results date for Guj. Terce Labs.?

No Upcoming Board Meetings

Has Guj. Terce Labs. declared dividend?

No Dividend History Available

Who are the peers of the Guj. Terce Labs.?

Guj. Terce Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Guj. Terce Labs. has below average management risk, growth, and capital structure, with a 1-year return of -2.13%.

Peers: The peers of Guj. Terce Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs., while Below Average management risk is found at Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med. Excellent growth is noted for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs., while Below Average growth is seen at Divi's Lab., Torrent Pharma, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, Veerhealth Care, and Vilin Bio Med. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs., while Below Average capital structure is noted for Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, and Vilin Bio Med.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while ANG Lifesciences has the lowest at -44.35%. Guj. Terce Labs. has a 1-year return of -2.13%, which is higher than ANG Lifesciences but lower than Divi's Lab. Additionally, ANG Lifesciences, Shree Ganesh Bio, and Veerhealth Care all have negative six-month returns.

What is the technical trend for Guj. Terce Labs.?

As of May 6, 2025, Guj. Terce Labs has shifted to a bearish technical trend, indicated by a bearish MACD, moving averages, and KST, with the stock trading at 54.99 and showing a significant year-to-date decline compared to the Sensex.

As of 6 May 2025, the technical trend for Guj. Terce Labs has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Additionally, both the Bollinger Bands and Dow Theory indicate a mildly bearish trend on the weekly and monthly time frames. The stock is currently trading at 54.99, showing a significant decline year-to-date compared to the Sensex.

What does Guj. Terce Labs. do?

Gujarat Terce Laboratories Ltd is a Micro Cap company that produces branded generic pharmaceuticals for the domestic market. As of March 2025, it reported net sales of 123 Cr and a net loss of 34 Cr.

Overview: <BR>Gujarat Terce Laboratories Ltd produces branded generic formulations for the domestic market and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1985, Gujarat Terce Laboratories has developed a diverse product range over its more than three-decade journey. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 123 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -34 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.44 <BR>Return on Equity: -11.06% <BR>Price to Book: 4.34<BR><BR>Contact Details: <BR>Address: 122/2 Ravi Estate, Bileshwarpura Chhatral Gandhinagar Gujarat : 382729 <BR>Tel: 91-079-6663 3706 <BR>Email: ho@gujaratterce.com <BR>Website: http://www.gujaratterce.com

Who are the top shareholders of the Guj. Terce Labs.?

The top shareholders of Guj. Terce Labs are Abundant Trade Link Private Limited with 14.5% and public shareholder Sagar Saxena with 1.39%. Individual investors hold a total of 59.34%, with no current institutional holdings.

The top shareholders of Guj. Terce Labs include Abundant Trade Link Private Limited, which holds the highest promoter stake at 14.5%. Additionally, the highest public shareholder is Sagar Saxena, with a holding of 1.39%. Overall, individual investors collectively hold a significant 59.34% of the company's shares. There are no institutional holdings from mutual funds or foreign institutional investors at this time.

Is Guj. Terce Labs. overvalued or undervalued?

As of November 17, 2025, Guj. Terce Labs. is considered very expensive and overvalued, with a PE ratio of -32.23 and poor stock performance, significantly lagging behind peers like Sun Pharma and Divi's Lab.

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.<BR><BR>In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contrasting sharply with the Sensex's positive return of 8.72%.

How has been the historical performance of Guj. Terce Labs.?

Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of -2.52 Cr in the most recent fiscal year, with significant decreases in revenue and operating profit. The company's financial metrics indicate ongoing challenges in generating cash from core operations.

Answer:<BR>The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Guj. Terce Labs reported net sales of 25.18 Cr, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also saw a decline from 36.86 Cr in March 2020. This resulted in an operating profit (PBDIT) of -1.96 Cr in March 2021, a stark contrast to the positive figures of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax was -2.53 Cr in March 2021, compared to 0.44 Cr in March 2020 and 0.35 Cr in March 2019, leading to a profit after tax of -2.52 Cr in March 2021, down from 0.28 Cr in March 2020 and 0.43 Cr in March 2019. The earnings per share (EPS) reflected this downturn, falling to -3.4 in March 2021 from 0.38 in March 2020 and 0.58 in March 2019. The company's total liabilities decreased to 21.70 Cr in March 2021 from 22.34 Cr in March 2020, while total assets also declined to 21.70 Cr from 22.34 Cr in the same period. Cash flow from operating activities was stagnant at 0.00 Cr in March 2021, indicating challenges in generating cash from core operations. Overall, the financial metrics indicate a concerning trend for Guj. Terce Labs, with declining revenues and increasing losses.

Are Gujarat Terce Laboratories Ltd latest results good or bad?

Gujarat Terce Laboratories Ltd's latest results are poor, with a significant drop in operating margin from 16.40% to 5.33% and a 71.88% decline in net profit compared to the previous quarter. The company's low Mojo Score of 21 and "Strong Sell" rating indicate serious operational and financial challenges.

Gujarat Terce Laboratories Ltd's latest results indicate significant challenges for the company. The operating margin has collapsed from 16.40% in the previous quarter to just 5.33%, which raises serious concerns about cost management and operational efficiency. Additionally, the net profit for Q2 FY26 has dropped by a staggering 71.88% compared to the previous quarter, falling to ₹0.45 crore.<BR><BR>While there was a year-on-year growth of 21.62% in net profit compared to Q2 FY25, the overall financial performance is overshadowed by the sharp decline in profitability and the dramatic margin compression. The company's Mojo Score is only 21 out of 100, and it carries a "Strong Sell" rating, reflecting a lack of investor confidence and serious operational distress.<BR><BR>Overall, the results can be characterized as poor, with the company facing significant operational and financial hurdles that need to be addressed to restore stability and investor trust.

Should I buy, sell or hold Gujarat Terce Laboratories Ltd?

Why is Gujarat Terce Laboratories Ltd falling/rising?

As of 30-Mar, Gujarat Terce Laboratories Ltd's stock price is Rs. 31.55, down 4.57%, marking a total decline of 21.11% over the last five days and hitting a new 52-week low of Rs. 29. The stock has significantly underperformed its sector and shows weak long-term fundamentals, contributing to a negative overall sentiment.

As of 30-Mar, Gujarat Terce Laboratories Ltd is experiencing a decline in its stock price, currently at Rs. 31.55, which reflects a change of -1.51 (-4.57%). The stock has been on a downward trend, having fallen consecutively for the last five days, resulting in a total decline of -21.11% during this period. Additionally, the stock has hit a new 52-week low of Rs. 29 today, indicating significant weakness.<BR><BR>In terms of performance, the stock has underperformed its sector by -3.04% today and has shown substantial losses over various time frames, including a -21.03% drop over the past month and a staggering -48.11% decline over the past year. This poor performance is compounded by the company's weak long-term fundamentals, including a low Return on Equity (ROE) of -17% and a poor EBIT to Interest ratio of 0.59, which suggests challenges in servicing its debt.<BR><BR>Despite some positive indicators, such as rising promoter confidence with a 3% increase in their stake, the overall sentiment remains negative due to the company's weak financial health and significant underperformance compared to the broader market. The stock's high volatility, with an intraday volatility of 10.49%, further reflects the uncertainty surrounding its future performance. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Guj. Terce Labs.?